Related Experiment Video
Updated: Apr 23, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
Clostridium difficile and pediatric inflammatory bowel disease: a prospective, comparative, multicenter, ESPGHAN
Massimo Martinelli1, Caterina Strisciuglio, Gabor Veres
1*Department of Translational Medical Science, Section of Pediatrics, University of Naples "Federico II," Naples, Italy; †First Department of Pediatrics, Semmelweis University, Budapest, Europe; ‡Department of Pediatrics, Hvidovre University Hospital, Hvidovre, Denmark; §Referral Center for Pediatric Gastroenterology and Nutrition, Children's Hospital Zagreb, Zagreb, Croatia; ‖Department of Pediatrics, University of Rome "La Sapienza," Rome, Italy; ¶Pediatric IBD Unit, Department of Pediatric Gastroenterology, Hepatology and Nutrition, Hospital Sant Joan de Déu, Barcelona, Spain; **Pediatric Gastroenterology and Nutrition Unit, Wolfson Medical Center, Tel Aviv University, Tel Aviv, Israel; ††Pediatric Gastroenterology Unit, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel; and ‡‡Department of Cellular and Molecular Biology and Pathology "Luigi Califano", University of Naples "Federico II," Naples, Italy.
Pediatric inflammatory bowel disease (IBD) patients show higher Clostridium difficile infection rates than celiac disease patients. C. difficile infection is linked to more active and severe IBD disease courses.
Area of Science:
- Pediatric Gastroenterology
- Infectious Diseases
- Microbiology
Background:
- Clostridium difficile infection (CDI) is a known complication in pediatric inflammatory bowel disease (IBD).
- The relationship between CDI and IBD disease activity requires further investigation.
- Comparative studies are needed to understand CDI prevalence in pediatric IBD versus other pediatric gastrointestinal conditions.
Purpose of the Study:
- To compare the incidence of Clostridium difficile infection in pediatric patients with IBD versus those with celiac disease.
- To evaluate the impact of C. difficile infection on the disease course of pediatric IBD patients.
Main Methods:
- A prospective, comparative, multicenter study enrolled 211 pediatric IBD patients and 112 pediatric celiac disease patients.
- Stool specimens were collected at 0, 6, and 12 months to test for C. difficile toxins A and B.
- Disease activity and clinical outcomes were monitored throughout the 12-month study period.
Main Results:
- Clostridium difficile infection occurred significantly more often in pediatric IBD patients (7.5%) compared to celiac disease patients (0.8%).
- CDI was associated with active colonic disease in 85.7% of infected IBD patients and correlated with increased disease activity at 6 and 12 months.
- CDI-positive IBD patients experienced higher hospitalization rates at 6 months and were more likely to initiate immunosuppressant/biologic therapy by 12 months.
Conclusions:
- Pediatric IBD is significantly associated with a higher prevalence of Clostridium difficile infection.
- C. difficile infection in pediatric IBD patients is linked to active colonic disease and a more severe overall disease course.
- These findings highlight the importance of monitoring for CDI in pediatric IBD management.
Related Concept Videos
Inflammatory Bowel Disease III: Crohn's Disease
Inflammatory Bowel Disease I: Introduction
Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory Bowel Disease II: Ulcerative Colitis
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

